GO:0042923 neuropeptide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042923 neuropeptide binding describes the selective, non-covalent and stoichiometric interaction of a protein with neuropeptides, which are peptide neurotransmitters or neuromodulators.
• Neuropeptide binding is the first step in neuropeptide signaling and is mediated by GPCRs, ion channels, and secreted neuropeptide-binding proteins.
• The binding kinetics and structural modes of neuropeptide-receptor interactions determine signal duration and specificity.
• Dysregulation of neuropeptide binding is linked to feeding disorders, pain, and neurodegenerative conditions.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of neuropeptide binding in vitro and in vivo.
• EDITGENE provides end-to-end CRISPR services to study neuropeptide binding, from library screening to bioinformatics.
Description
Neuropeptide binding (GO:0042923) is a molecular function defined as the selective, non-covalent and stoichiometric interaction with neuropeptides, which are peptides with direct synaptic effects (peptide neurotransmitters) or indirect modulatory effects on the nervous system (peptide neuromodulators). This function is fundamental to intercellular communication in the nervous system and is mediated by diverse protein families, including G protein-coupled receptors (GPCRs), ligand-gated ion channels, and secreted binding proteins. Researchers study neuropeptide binding to understand how the nervous system processes feeding, pain, and stress signals, and to develop therapeutics targeting these pathways. The binding event is highly regulated and its kinetics influence the duration and strength of neuropeptide signaling. Recent structural and kinetic studies have revealed that even closely related neuropeptide-gated ion channels can exhibit flipped binding modes for the same agonist, highlighting the complexity of this interaction. This article provides a research-grade overview of the mechanism, key genes, and experimental methods for studying neuropeptide binding, with a focus on CRISPR-based models.
neuropeptide binding At A Glance
| GO ID | GO:0042923 |
|---|---|
| GO term | neuropeptide binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Selective, non-covalent and stoichiometric interaction with neuropeptides |
| Definition source | QuickGO |
| Related functions | neuropeptide receptor activity, neuropeptide hormone activity |
| Cellular location | Plasma membrane, extracellular space, synaptic cleft |
| Representative proteins | Orexin receptors, neuropeptide FF receptor, neuropeptide-gated ion channels |
What Is GO:0042923?
Neuropeptide binding is the molecular function of interacting selectively and non-covalently with neuropeptides, which are peptides that act as neurotransmitters or neuromodulators in the nervous system. This binding is stoichiometric, meaning that a defined number of neuropeptide molecules bind to a defined number of protein binding sites, and it does not involve covalent modification of the ligand or the binding protein. The function is essential for transmitting neuropeptide signals across synapses or through volume transmission.
Why Is neuropeptide binding Important in Cell Biology?
Neuropeptide binding is a central molecular event in neural signaling and is critical for understanding how the nervous system regulates feeding, pain, stress, and reward. Dysregulation of this function is implicated in a wide range of disorders, from sleep and metabolic diseases to chronic pain and neurodegeneration. Because neuropeptide binding is the first step in signal transduction, it is a prime target for therapeutic intervention. Moreover, the binding properties of neuropeptides and their receptors determine the specificity and duration of signaling, which is essential for normal physiology. Studying neuropeptide binding also provides insight into the evolution of ligand-receptor pairs and the design of drugs that can selectively modulate these interactions.
• Neuropeptide binding initiates signaling cascades that regulate feeding behavior and energy homeostasis.
• It is essential for pain perception and analgesia, as shown for neuropeptide FF.
• It mediates neuroregeneration after stroke through engineered neuropeptide-loaded extracellular vesicles.
• It underlies the action of orexins in sleep and arousal.
• It is a target for drug discovery in metabolic and neurological disorders.
• It determines the specificity of neuropeptide-gated ion channel activation.
• It is required for neuropeptide secretion and synaptic transmission.
• It can be modulated by β-arrestin recruitment to neuropeptide GPCRs.
• It is a key function for understanding neuropeptide evolution and receptor-ligand co-evolution.
• It provides a basis for CRISPR-based screens to identify novel neuropeptide binding proteins.
Molecular Mechanism of neuropeptide binding
Ligand recognition and binding site architecture
In simple terms: The neuropeptide fits into a specific pocket on the receptor protein, like a key in a lock.
Neuropeptide binding is initiated by the recognition of the neuropeptide by a complementary binding site on the target protein. Structural studies of neuropeptide-gated ion channels have revealed that the binding pocket is formed by extracellular loops and transmembrane helices, and that the same agonist can adopt flipped binding modes in closely related channels. For GPCRs, the binding site is typically located within the transmembrane helical bundle, as shown for orexin receptors. The binding is non-covalent and stoichiometric, relying on hydrogen bonds, ionic interactions, and hydrophobic contacts.
Conformational changes and signal initiation
In simple terms: Once the neuropeptide binds, the receptor changes shape to start a signal inside the cell.
Binding of the neuropeptide induces conformational changes in the receptor that propagate to the intracellular side, enabling coupling to G proteins or opening of ion channels. For neuropeptide-gated ion channels, agonist binding leads to pore opening and ion flux, which can be modulated by the binding mode. The kinetics of these conformational changes determine the duration of the signal, as reviewed for neuropeptide-receptor interactions.
Binding kinetics and affinity
In simple terms: How tightly and how long the neuropeptide stays bound affects the strength and length of the signal.
The kinetic profile of neuropeptide-receptor interactions, including association and dissociation rates, dictates the signaling outcome. High-affinity binding can lead to sustained signaling, while rapid dissociation may result in transient responses. These parameters are critical for drug design and for understanding physiological responses to neuropeptides.
Regulation by accessory proteins and arrestins
In simple terms: Other proteins can interact with the receptor to turn the signal off or change it.
Neuropeptide binding can be regulated by accessory proteins such as β-arrestins, which bind to activated GPCRs and promote desensitization and internalization. Candidate β-arrestin binding sites have been identified in Drosophila neuropeptide GPCRs, suggesting conserved regulatory mechanisms. Additionally, membrane-binding domains of proteins like RIM and MUNC13 are essential for neuropeptide secretion, indirectly influencing the availability of neuropeptides for binding.
Structural diversity and binding modes
In simple terms: Different receptors can bind the same neuropeptide in different ways, leading to different responses.
Recent structural work has shown that closely related neuropeptide-gated ion channels can exhibit flipped binding modes for the same agonist, which may contribute to functional diversity. This structural plasticity underscores the importance of determining high-resolution structures to understand specificity and to design selective modulators.
Key Genes Involved in GO:0042923 neuropeptide binding
The following genes encode proteins that directly bind neuropeptides or are critical for neuropeptide binding and signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HCRTR1 | Orexin receptor 1, binds orexin-A and orexin-B | Feeding, sleep, and arousal disorders |
| HCRTR2 | Orexin receptor 2, binds orexins | Narcolepsy and metabolic research |
| NPFFR1 | Neuropeptide FF receptor 1 | Pain and analgesia |
| NPFFR2 | Neuropeptide FF receptor 2 | Pain modulation |
| GLRA1 | Glycine receptor alpha 1, binds neuropeptides as modulators | Startle disease and inhibitory signaling |
| GABRA1 | GABA-A receptor subunit, modulated by neuropeptides | Epilepsy and anxiety |
| BDNF | Brain-derived neurotrophic factor, neuropeptide with binding partners | Neuroregeneration and stroke |
| RIMS1 | RIM1, involved in neuropeptide secretion | Synaptic transmission |
| UNC13A | MUNC13-1, essential for neuropeptide secretion | Neurotransmitter release |
| ARRB1 | β-arrestin 1, binds activated neuropeptide GPCRs | Receptor desensitization |
| ARRB2 | β-arrestin 2, regulates neuropeptide GPCR signaling | GPCR trafficking |
| NPSR1 | Neuropeptide S receptor | Anxiety and sleep |
| TACR1 | Substance P receptor, binds neurokinin A | Pain and inflammation |
| OPRM1 | Mu-opioid receptor, binds endogenous opioid peptides | Analgesia and addiction |
| OPRK1 | Kappa-opioid receptor, binds dynorphins | Stress and mood |
| NPY1R | Neuropeptide Y receptor Y1 | Feeding and energy balance |
| SSTR2 | Somatostatin receptor 2 | Neuroendocrine tumors |
How Is neuropeptide binding Regulated?
Neuropeptide binding is regulated at multiple levels. The availability of neuropeptides is controlled by secretion machinery, including RIM and MUNC13 membrane-binding domains, which are essential for neuropeptide secretion. Receptor desensitization and internalization are regulated by β-arrestin binding to activated GPCRs, as predicted for Drosophila neuropeptide GPCRs. Additionally, the kinetic profile of neuropeptide-receptor interactions, including association and dissociation rates, can be modulated by post-translational modifications and allosteric regulators. These regulatory mechanisms ensure that neuropeptide signaling is tightly controlled in time and space.
neuropeptide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HCRTR1 | Narcolepsy, obesity | Knockout mouse, point-mutation knock-in |
| HCRTR2 | Narcolepsy, sleep disorders | Knockout rat, overexpression cell line |
| NPFFR1 | Chronic pain | Knockout mouse, knock-in humanized receptor |
| NPFFR2 | Pain sensitivity | Point-mutation knock-in, overexpression |
| BDNF | Stroke, neurodegeneration | Knock-in for tagged BDNF, overexpression in MSC-EVs |
Neuropeptide binding in metabolic and sleep disorders
Orexin neuropeptides and their receptors are critical regulators of feeding and sleep. Dysregulation of orexin binding has been linked to narcolepsy and obesity, making HCRTR1 and HCRTR2 prime targets for therapeutic development. The binding kinetics of orexin to its receptors influence the duration of arousal and feeding signals.
Neuropeptide binding in pain and analgesia
Neuropeptide FF and its receptors modulate pain perception. Alterations in neuropeptide FF binding have been associated with altered pain sensitivity and analgesic responses. Targeting NPFFR1 and NPFFR2 with selective ligands could provide new avenues for pain management.
Neuropeptide binding in neuroregeneration
Engineered extracellular vesicles loaded with BDNF-enhancing neuropeptides have been shown to enhance post-stroke neuroregeneration via intranasal delivery, highlighting the therapeutic potential of modulating neuropeptide binding and signaling. The binding of these neuropeptides to their receptors on target cells is a key step in promoting recovery.
From neuropeptide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HCRTR1 affect feeding behavior? | HCRTR1 knockout mouse |
| Does a point mutation in NPFFR1 alter ligand binding affinity? | NPFFR1 point-mutation knock-in cell line |
| Can tagged orexin receptor be used for live-cell imaging? | HCRTR1 tagged knock-in |
| Does overexpression of BDNF enhance neuroregeneration? | BDNF overexpression in mesenchymal stem cells |
| Which genes are essential for neuropeptide binding? | Genome-wide CRISPR knockout library screening |
| How does β-arrestin recruitment affect receptor internalization? | ARRB1/ARRB2 knockout cells |
How to Study the neuropeptide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and kinetics of neuropeptide binding | Receptor characterization |
| Surface plasmon resonance | Real-time binding kinetics | Drug screening |
| Cryo-EM | High-resolution structure of binding complexes | Mechanistic studies |
| Patch-clamp | Ion channel activity upon neuropeptide binding | Neuropeptide-gated ion channels |
| Calcium imaging | Intracellular calcium flux | GPCR activation |
| CRISPR knockout screening | Genes essential for neuropeptide binding | Functional genomics |
| RNA-seq | Transcriptional changes upon neuropeptide binding | Pathway analysis |
Binding assays
Radioligand binding assays and surface plasmon resonance (SPR) are used to measure the affinity and kinetics of neuropeptide-receptor interactions. These methods provide quantitative parameters such as Kd and kon/koff, which are essential for understanding signaling duration.
Structural biology
Cryo-electron microscopy and X-ray crystallography have revealed the structural basis of neuropeptide binding, including flipped binding modes in related ion channels and the architecture of orexin receptors. These techniques provide atomic-level detail for drug design.
Functional assays
Calcium imaging, patch-clamp electrophysiology, and cAMP assays are used to measure downstream signaling upon neuropeptide binding. These functional readouts link binding to physiological responses.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout screens can identify genes required for neuropeptide binding and signaling. Bioinformatics analysis of transcriptomic and proteomic data can reveal expression patterns and pathways associated with neuropeptide binding.
How CRISPR Can Be Used to Study GO:0042923 neuropeptide binding
Knockout
CRISPR knockout of neuropeptide receptor genes, such as HCRTR1 or NPFFR1, allows researchers to study the loss of neuropeptide binding and its physiological consequences. Knockout models can reveal whether a specific receptor is required for feeding, pain, or sleep behaviors.
Point Mutation
Point mutations can be introduced into the binding pocket of neuropeptide receptors to dissect the contribution of individual amino acids to ligand binding affinity and specificity. This approach is valuable for understanding structure-function relationships.
Knock-in
Knock-in of tagged or humanized neuropeptide receptors enables live-cell imaging and species-specific drug testing. For example, a tagged orexin receptor can be used to track receptor trafficking upon neuropeptide binding.
Overexpression
Overexpression of neuropeptides or their receptors in cell lines or engineered vesicles can enhance neuropeptide binding and signaling for therapeutic applications, such as BDNF-enhancing neuropeptides in stroke models.
How EDITGENE Supports neuropeptide binding Research
Researchers studying neuropeptide binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease model. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional interrogation of neuropeptide binding mechanisms.
Contact EDITGENE today to design your custom CRISPR model for neuropeptide binding research.
Frequently Asked Questions About neuropeptide binding
What is neuropeptide binding?
Neuropeptide binding (GO:0042923) is the selective, non-covalent and stoichiometric interaction with neuropeptides, which are peptide neurotransmitters or neuromodulators.
What genes are involved in neuropeptide binding?
Key genes include HCRTR1, HCRTR2, NPFFR1, NPFFR2, and OPRM1, which encode receptors that bind neuropeptides.
How is neuropeptide binding studied?
It is studied using binding assays, structural biology, functional assays, and CRISPR screens.
What diseases are associated with neuropeptide binding?
Disorders include narcolepsy, obesity, chronic pain, and stroke.
What is the GO ID for neuropeptide binding?
The GO ID is GO:0042923.
What are the synonyms for neuropeptide binding?
There are no synonyms listed in QuickGO for GO:0042923.
How does neuropeptide binding initiate signaling?
Binding induces conformational changes in the receptor, leading to G protein activation or ion channel opening.
Can CRISPR be used to study neuropeptide binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting neuropeptide binding mechanisms.
What is the role of β-arrestin in neuropeptide binding?
β-arrestin binds to activated neuropeptide GPCRs and regulates receptor desensitization and internalization.
What are the kinetics of neuropeptide binding?
Binding kinetics, including association and dissociation rates, determine the duration and strength of neuropeptide signaling.
Conclusion
Neuropeptide binding (GO:0042923) is a fundamental molecular function that underlies neural communication and is implicated in diverse physiological and pathological processes. Understanding its mechanism, key genes, and regulation is essential for developing targeted therapies. CRISPR-based models provide powerful tools to dissect the causal roles of neuropeptide binding proteins in health and disease. EDITGENE offers comprehensive services to support these research efforts.
References
- 1. Murphy FH et al.. 2025. RIM and MUNC13 membrane-binding domains are essential for neuropeptide secretion.. J Cell Biol 224(7) PMID: 40353777
- 2. Kalienkova V et al.. 2024. Structural basis for excitatory neuropeptide signaling.. Nat Struct Mol Biol 31(4):717-726 PMID: 38337033
- 3. Sakurai T et al.. 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.. Cell 92(4):573-85 PMID: 9491897
- 4. Claereboudt EJS et al.. 2025. Flipped binding modes for the same agonist in closely related neuropeptide-gated ion channels.. Biophys J 124(7):1049-1057 PMID: 39801005
- 5. Taghert PH. 2022. The incidence of candidate binding sites for β-arrestin in Drosophila neuropeptide GPCRs.. PLoS One 17(11):e0275410 PMID: 36318573
- 6. Nederpelt I et al.. 2016. Kinetic Profile of Neuropeptide-Receptor Interactions.. Trends Neurosci 39(12):830-839 PMID: 27793433
- 7. Roumy M et al.. 1998. Neuropeptide FF, pain and analgesia.. Eur J Pharmacol 345(1):1-11 PMID: 9593588
- 8. Kim JE et al.. 2025. Engineered MSC-EVs loaded with BDNF-enhancing neuropeptides via a non-disruptive method enhance post-stroke neuroregeneration via intranasal delivery.. J Nanobiotechnology 23(1):594 PMID: 40883738
